Wall Street analysts expect HCW Biologics to report a net loss of $1.98 per share for the second quarter of 2026, while the stock currently trades at approximately $1.56 with a consensus price target of $8.00.
The primary focus for this report is the preliminary human data readout for HCW9302, a fusion immunotherapeutic being evaluated in a Phase 1 study for patients with alopecia areata.
Investors are particularly attentive to regulatory T-cell expansion and SALT score reductions following encouraging early cohort results earlier this summer. However, liquidity remains a major concern, as management has recently maintained a going-concern warning despite successful private placement rounds and a significant licensing agreement with Beijing Trimmune Biotech.